Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE
Bank of America Corp DE has increased its stock holdings in Xenon Pharmaceuticals Inc. by 19.8% during the first quarter, now owning 265,267 shares valued at $15.42 million. Other institutional investors have also adjusted their positions in XENE, with hedge funds and institutional investors collectively owning 95.45% of the stock. Despite a recent trading dip, analysts maintain a "Buy" consensus rating for Xenon Pharmaceuticals, with an average target price of $77.13.
Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?
Xenon Pharmaceuticals recently reported wider Q2 2026 losses, reaching US$110.74 million, as it funds its ion-channel neurology pipeline, particularly ahead of the planned U.S. NDA submission for azetukalner. These rising losses bring funding needs and potential dilution into focus, prompting investors to assess the company's transition from an R&D focus to an early commercial stage. Despite these challenges, analysts project significant revenue growth and a fair value suggesting a 28% upside.
TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE
TimesSquare Capital Management LLC has acquired 451,593 shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a new position valued at approximately $27.3 million, giving them a 0.47% stake in the biopharmaceutical company. Institutional investors collectively own 95.45% of the stock. Xenon Pharmaceuticals recently reported better-than-expected quarterly adjusted EPS and maintains a "Buy" consensus rating from analysts, despite recent insider share sales.
Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds
Xenon Pharmaceuticals (XENE) recently reported a Q2 net loss of US$110.74 million but is considered 22.6% undervalued, with a fair value of $80.56 compared to its current price of $62.35. This valuation is driven by expectations for its epilepsy drug azetukalner, despite risks if clinical data disappoints or rival therapies emerge. The company's P/B ratio of 4.9x is high compared to the US Biotechs average but low compared to its peers.
Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding
Xenon Pharmaceuticals' Independent Director Steven Gannon recently sold a significant 84% of his holdings, amounting to US$641k worth of stock. This follows another substantial sale by President Ian Mortimer in the last year, suggesting insiders might view lower prices as reasonable. While insider selling can be a cautionary signal, it's noted that the company's insiders hold a relatively small percentage of shares overall.
Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE
Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling about $774,000. Xenon Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on neurological and pain disorders, reported better-than-expected quarterly EPS.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from seventeen brokerages, with an average 12-month price target of $77.13. The company's stock is currently trading below its recent high, with institutional investors holding a significant 95.45% stake. Recent insider selling has also been noted, with key directors selling shares worth approximately $774,000 in the last three months.
Xenon Pharmaceuticals Director Sold Shares Worth Over $640K
Steven Gannon, a Director at Xenon Pharmaceuticals (XENE), reported the sale of common shares totaling $640,550 on August 11, 2026. The transactions were executed at a weighted-average price of $64.055 per share. Following this sale, Gannon directly holds 1,870 common shares in the company.
Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct
Director Steven Gannon of Xenon Pharmaceuticals (XENE) sold 10,000 shares for $64.06 per share, totaling $640,600, reducing his direct holdings to 1,870 shares. This sale contributes to a broader trend of 13 insider sells and no buys over the past year at Xenon, signaling potential caution, although some institutional investors are increasing their stakes. The company, a clinical-stage biopharmaceutical firm, is valued at $6.21 billion and is developing therapeutics for neurological disorders.
Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients
Wellington Management Group LLP and its affiliates have reported a passive ownership stake of approximately 1.47% in Xenon Pharmaceuticals Inc. (XENE) common stock. This stake, representing 1,425,492 shares, is held for advisory clients across various Wellington investment entities, with no single client owning more than five percent. The filing indicates shared voting and dispositive power over these securities, emphasizing their role as investment advisers.
Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64
Xenon Pharmaceuticals director Steven Gannon sold 10,000 Common Shares on August 11, 2026, at a weighted-average price of $64.055 per share. The shares were sold in multiple transactions ranging from $64.0517 to $64.078. Following this transaction, Gannon directly holds 1,870 Common Shares of Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. Q2 2026: Revenue $0 EPS $(1.11) — 10-Q Summary
Xenon Pharmaceuticals Inc. reported its Q2 2026 financial results, showing no product or collaboration revenue and a net loss of $110.7 million, or $(1.11) diluted loss per share. This represents a wider net loss compared to Q2 2025, primarily due to increased R&D spending and operational build-out for late-stage clinical programs. Despite the losses, the company maintains strong cash balances to support ongoing development and planned trial completions.
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy
H.C. Wainwright maintained a Buy rating and a $74.00 price target for Xenon Pharmaceuticals (NASDAQ: XENE), citing the FDA's lack of concerns regarding their pre-NDA meeting and the company's belief that their drug package supports approval of all four doses. The stock has seen an 89.5% return over the past year, and the company is actively preparing its launch infrastructure for eventual approval. Additionally, the article mentions 10x Genomics, which reported better-than-expected Q2 2026 results and raised its full-year revenue outlook, driven by strong demand for its new Atera spatial platform.
HC Wainwright Issues Positive Outlook for XENE Earnings
HC Wainwright has revised its earnings outlook for Xenon Pharmaceuticals (NASDAQ:XENE), predicting reduced losses for Q3 2026 and subsequent fiscal years, and maintaining a "Buy" rating with a $74 price target. The biopharmaceutical company recently surpassed analyst expectations for its quarterly loss. Despite these positive revisions, Xenon Pharmaceuticals is still forecast to remain unprofitable through 2029, though the improved long-term outlook suggests a trajectory toward breakeven.
Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE
Quantinno Capital Management LP significantly increased its stake in Xenon Pharmaceuticals Inc. by 125.1% in the first quarter, acquiring an additional 30,816 shares. The biopharmaceutical company, which has no product sales, reported a narrower-than-expected quarterly loss of $1.11 per share. Analyst sentiment remains largely positive with a "Buy" rating and an average price target of $77.13, primarily due to pipeline progress, especially the planned azetukalner NDA filing.
FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals reported a net loss of US$110.74 million in Q2 2026, but its successful pre-NDA meeting with the FDA for azetukalner and a US$1.20 billion cash balance position it for potential regulatory milestones. The company is on track to submit an NDA for azetukalner for focal onset seizures this quarter, which is a key catalyst for future revenue expectations. Despite increased losses, Xenon aims to advance multiple late-stage neuroscience programs while managing execution risk.
Xenon Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $81.21, Implies 26% Upside
Xenon Pharmaceuticals Inc. (XENE) has seen its average 12-month price target increased by analysts to $81.21, up from $80.8, with a potential upside of approximately 26% based on its recent closing price. The consensus rating remains a "Buy" from 18 covering analysts, indicating strong positive sentiment for the stock.
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ...
Xenon Pharmaceuticals Inc (XENE) reported its Q2 2026 earnings, highlighting a strong cash position of $1.2 billion, funding operations into 2029. The company is on track to submit an NDA for azetukalner in focal seizures this quarter, following a successful pre-NDA meeting with the FDA and positive Phase III trial results. Xenon also discussed its broad pipeline including five additional Phase III studies for azetukalner and advancements in its pain portfolio, while addressing potential challenges such as regulatory approval uncertainties and market competition.
XENON PHARMACEUTICALS INC. : WEDBUSH RAISES TARGET PRICE TO $71 FROM $63
Wedbush has increased its target price for Xenon Pharmaceuticals Inc. (XENE.O) shares to $71, up from the previous target of $63. This adjustment suggests an improved outlook from the analyst firm for the pharmaceutical company's stock. The information was released by Reuters on August 7, 2026.
California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE
The California State Teachers Retirement System increased its stake in Xenon Pharmaceuticals Inc. by 64% in the first quarter, purchasing 36,183 additional shares to bring its total holding to 92,747 shares valued at approximately $5.4 million. Institutional investors now own 95.45% of the company, and analysts maintain a consensus "Buy" rating with an average price target of $77.20. The biopharmaceutical company recently reported a quarterly loss of $1.11 per share, outperforming analyst expectations.
FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals (XENE) recently reported second-quarter 2026 results with a net loss of US$110.74 million, yet its successful pre-NDA meeting with the FDA for azetukalner and a US$1.20 billion cash balance position it for significant progress in its neuroscience programs. The company is on track to submit an NDA for azetukalner for focal onset seizures, a key catalyst driving future revenue expectations, despite ongoing quarterly losses. Analysts project a potential revenue of $384.6 million and earnings of $72.8 million by 2029, suggesting a substantial upside to its current price if azetukalner proves commercially viable.
Xenon Pharmaceuticals Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals (NASDAQ: XENE) reported its Q2 2026 earnings, with revenue of $151 million, beating consensus EPS by $0.05. The company highlighted "extraordinary customer response" to its new Atera platform, with booked orders already exceeding the 40 instruments expected to ship in 2026, though manufacturing capacity remains a constraint. Xenon Pharmaceuticals raised its full-year 2026 revenue outlook to $610 million-$630 million and discussed the significant impact of AI on demand for its single-cell and spatial technologies in biological research and drug discovery.
Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says
Xenon Pharmaceuticals' azetukalner NDA filing remains on track following a productive pre-NDA meeting with the FDA, according to RBC. However, the full article content is only available to premium subscribers.
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ...
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 earnings call highlighted significant progress in advancing azetukalner, with a successful pre-NDA meeting for focal seizures and a strong cash position of $1.2 billion, funding operations into 2029. The company also detailed its broad pipeline, including five additional Phase III studies for azetukalner in epilepsy and neuropsychiatry, and progress in its pain portfolio. However, challenges remain, such as pending regulatory approval, significant market competition, and early-stage pain programs lacking specific efficacy data.
Xenon Reports Q2 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals Inc. announced its Q2 2026 financial results, highlighted by the continued progress of its lead drug azetukalner, with an NDA submission for FOS on track for Q3 2026 and Phase 3 data for MDD expected in H1 2027. The company reported $1.2 billion in cash, cash equivalents, and marketable securities, providing a cash runway into 2029. Xenon also provided updates on its pain pipeline and other early-stage R&D programs, showcasing a broad development portfolio.
Xenon Pharmaceuticals earnings on deck as FDA approval push nears
Xenon Pharmaceuticals is set to release its second-quarter earnings, with investors keenly watching its cash position and regulatory timeline as it approaches an FDA submission for its drug, azetukalner. Analysts anticipate a loss of $1.14 per share on $1.5 million in revenue. The company is expected to provide an update on its planned Q3 2026 NDA submission for azetukalner, a promising epilepsy treatment, and insights into its financial runway given ongoing clinical trials.
FMR LLC and Abigail Johnson report 9.9% Xenon Pharmaceuticals (XENE) holding
FMR LLC and Abigail Johnson have reported a 9.9% beneficial ownership stake in Xenon Pharmaceuticals Inc. (XENE) as of June 30, 2026. FMR LLC holds 9,599,498 common shares with sole dispositive power and sole voting power over 9,591,437 shares, while Abigail P. Johnson also has sole dispositive power over the same number of shares but no voting power. The shares are held on behalf of various clients, with no single underlying person holding more than five percent of the outstanding common stock.
Xenon Pharmaceuticals Inc. $XENE Shares Bought by Sei Investments Co.
Sei Investments Co. significantly increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 160.8% in the first quarter, now owning 114,381 shares valued at approximately $6.65 million. Other institutional investors also adjusted their holdings, contributing to institutional and hedge fund ownership of 95.45% of the company. Despite recent insider selling by two directors, analyst sentiment remains largely positive with a "Buy" consensus rating and an average price target of $77.20.
Responsive Playbooks and the XENE Inflection
This article analyzes Xenon Pharmaceuticals Inc. (NASDAQ: XENE), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis, indicating a favorable 36.9:1 risk-reward setup for a potential 10.9% gain.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. has announced equity inducement grants to eleven new non-officer employees, consisting of 32,758 share options and 19,013 restricted share units (RSUs). These grants were approved by the Compensation Committee and were material to the employees joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $64.19 and vest over four years, while the RSUs vest over four anniversaries of the grant date.
Price to sales forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE
This article provides a brief financial update on Xenon Pharmaceuticals Inc. (NASDAQ: XENE), focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication with no trades. The content is primarily a data point from TradingView without further detailed analysis.
Price to sales forward of Xenon Pharmaceuticals Inc. – HAM:XP0
This article provides financial data for Xenon Pharmaceuticals Inc. (HAM:XP0) focusing on its price-to-sales forward ratio. It indicates that the market is currently closed with no trades recorded. The content is primarily a data page from TradingView.
Xenon Sets $64.19 Option Price for 11 New Employees' Grants
Xenon Pharmaceuticals announced equity inducement grants for eleven new non-officer employees, effective July 30, 2026. The grants include 32,758 share options with an exercise price of $64.19 per common share and 19,013 restricted share units (RSUs). These awards, approved under Nasdaq Listing Rule 5635(c)(4), aim to incentivize new hires and will vest over four years, with options and RSUs subject to continued employment.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
This article from Xenon Pharmaceuticals reports on inducement grants made under Nasdaq Listing Rule 5635(c)(4). The content provided is a security check, indicating further details are likely behind this initial gate.
Price to cash flow ratio of Xenon Pharmaceuticals Inc. – HAM:XP0
This article displays financial information for Xenon Pharmaceuticals Inc. (HAM:XP0), specifically its price to cash flow ratio. It notes that the market is closed and no trades have occurred for this stock. The content primarily focuses on the company's financial overview within the TradingView platform.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to eleven new non-officer employees, consisting of 32,758 share options and 19,013 restricted share units (RSUs). These grants were approved by the Compensation Committee of the Company’s Board of Directors as inducements for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $64.19 and vest over four years, while the RSUs vest 25% annually over four years, both subject to continued service.
Xenon Pharmaceuticals Inc (XENE) Financial Health: Profitability & Balance Sheet Analysis
Xenon Pharmaceuticals Inc (XENE) has a current financial score of 6.41, ranking 249 out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue saw a 100% year-over-year decrease, and its net profit decreased by 57.27%. Many key financial metrics related to quality of earnings, operational efficiency, growth potential, and shareholder returns have not yet been disclosed by the company.
Xenon to Report Q2 2026 Financial Results on August 6, 2026
Xenon Pharmaceuticals Inc. announced it will report its second-quarter 2026 financial results and provide a business update on Thursday, August 6, 2026, after the close of U.S. financial markets. The company, focused on neuroscience, will host a webcast and conference call to discuss its financials and advancements in its drug discovery and clinical development programs. Key topics will include its lead molecule azetukalner, currently in Phase 3 trials, and its early-stage portfolio of potassium and sodium channel modulators.
Xenon plans Aug. 6 webcast for results and business update
Xenon Pharmaceuticals (Nasdaq: XENE) will report its Q2 2026 financial results and provide a business update on Thursday, August 6, 2026, after the U.S. markets close. A webcast and company presentation will follow at 4:30 p.m. ET. The company will likely discuss its lead molecule, azetukalner, which is in Phase 3 clinical trials, and early-stage KV7 and NaV1.7 programs.
Xenon Pharmaceuticals Inc (XENE) Institutional Confidence
Xenon Pharmaceuticals Inc (XENE) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional ownership stands at 116.66%, a 21.96% increase quarter-over-quarter. Paul Tudor Jones is the largest institutional shareholder, holding 534.69K shares, which represents 0.51% of outstanding shares.
Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Xenon Pharmaceuticals Inc (XENE) shareholder structure, listing major shareholders, their proportion of holdings, and a classification of shareholder types. It also includes institutional shareholding trends over several quarters and recent shareholder activity with changes in holdings for top investment firms.
Xenon Pharmaceuticals Inc (XENE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Xenon Pharmaceuticals Inc (XENE) stock, focusing on its dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years, indicating no payout history. The page also presents current stock performance data, market capitalization, and links to other financial analysis tools.
Understanding the Setup: (XENE) and Scalable Risk
This article provides an in-depth analysis of Xenon Pharmaceuticals Inc. (XENE) using AI models to suggest trading strategies. It highlights a near-term neutral sentiment amidst mid and long-term strength, pointing out a significant short setup with a 34.6:1 risk-reward ratio. The analysis includes position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for various holding periods.
Xenon Pharmaceuticals (XENE) Stifel 2025 Healthcare Conference Summary
This article summarizes Xenon Pharmaceuticals' (XENE) presentation at the Stifel 2025 Healthcare Conference. Key updates include the full enrollment of azetukalner's Phase III X-TOLE2 trial for epilepsy, with data expected in early 2026, and ongoing Phase III trials for major depressive disorder and bipolar depression. The company also highlighted its early-stage pain portfolio and anticipated multiple catalysts, including Phase III readouts and proof-of-concept data.
Xenon Pharmaceuticals (XENE) Q1 2025 earnings summary
Xenon Pharmaceuticals reported a Q1 2025 net loss of $65.0 million, an increase from the previous year, driven by higher R&D and G&A expenses. The company is nearing completion of patient recruitment for its pivotal XTOL-2/X-TOLE2 phase 3 epilepsy study, with top-line results expected early 2026, and is expanding clinical development for azetukalner into major depressive disorder and bipolar depression. Xenon Pharmaceuticals maintains a cash runway sufficient to fund operations into 2027, supporting its late-stage and early-stage pipeline development.
Xenon Pharmaceuticals advances with strong Phase 3 epilepsy data, eyeing NDA filing in 2026.
Xenon Pharmaceuticals is progressing with its lead drug candidate, azetukalner, for refractory focal onset seizures, showing strong effectiveness in Phase 3 trials and targeting an NDA filing in Q3 2026. The company is well-funded through 2029 for ongoing trials in other neurological conditions and is building commercial capabilities, though it acknowledges regulatory and commercial risks.
Price to sales forward of Xenon Pharmaceuticals Inc. – GETTEX:XP0
This article provides financial data, specifically the "Price to sales forward" value, for Xenon Pharmaceuticals Inc. (GETTEX:XP0). It highlights that the market was closed with no trades at the time of the report. The content appears to be a snapshot from a financial trading platform, offering an overview of the company's financial indicators.
Price to sales forward of Xenon Pharmaceuticals Inc. – TRADEGATE:XP0
This page provides financial data for Xenon Pharmaceuticals Inc. (TRADEGATE:XP0), specifically focusing on its forward price-to-sales ratio. The content indicates that the market was closed at the time of viewing, with no current trades.
Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds
Xenon Pharmaceuticals (XENE) is attracting investor attention due to its recent stock performance and late-stage epilepsy program. While a common valuation narrative suggests the company is 14.4% undervalued based on aggressive growth projections and future earnings, this hinges on successful clinical trials and favorable reimbursement. Investors are advised to assess the risks and rewards, particularly in comparison to industry P/B ratios.
Xenon Pharmaceuticals (XENE) Could Be 14% Undervalued If Its Epilepsy Narrative Holds
Xenon Pharmaceuticals (XENE) is seen as potentially 14.4% undervalued, with a fair value estimated at $80.56, largely based on its late-stage epilepsy program for azetukalner. Bulls highlight recent stock gains and the potential for significant revenue growth if clinical trials are successful, while bears point to ongoing losses and trial risks. The valuation, however, relies heavily on favorable clinical data and reimbursement, and its price-to-book ratio is higher than the industry average.
